Literature DB >> 19737573

Exploring kainate receptor pharmacology using molecular dynamics simulations.

Pekka A Postila1, Geoffrey T Swanson, Olli T Pentikäinen.   

Abstract

Ionotropic glutamate receptors (iGluRs) are enticing targets for pharmaceutical research; however, the search for selective ligands is a laborious experimental process. Here we introduce a purely computational procedure as an approach to evaluate ligand-iGluR pharmacology. The ligands are docked into the closed ligand-binding domain and during the molecular dynamics (MD) simulation the bi-lobed interface either opens (partial agonist/antagonist) or stays closed (agonist) according to the properties of the ligand. The procedure is tested with closely related set of analogs of the marine toxin dysiherbaine bound to GluK1 kainate receptor. The modeling is set against the abundant binding data and electrophysiological analyses to test reproducibility and predictive value of the procedure. The MD simulations produce detailed binding modes for analogs, which in turn are used to define structure-activity relationships. The simulations suggest correctly that majority of the analogs induce full domain closure (agonists) but also distinguish exceptions generated by partial agonists and antagonists. Moreover, we report ligand-induced opening of the GluK1 ligand-binding domain in free MD simulations. The strong correlation between in silico analysis and the experimental data imply that MD simulations can be utilized as a predictive tool for iGluR pharmacology and functional classification of ligands. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737573      PMCID: PMC2876335          DOI: 10.1016/j.neuropharm.2009.08.019

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  46 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

Authors:  C N Sang; N M Ramadan; R G Wallihan; A S Chappell; F G Freitag; T R Smith; S D Silberstein; K W Johnson; L A Phebus; D Bleakman; P L Ornstein; B Arnold; S J Tepper; F Vandenhende
Journal:  Cephalalgia       Date:  2004-07       Impact factor: 6.292

3.  Allosteric mechanism in AMPA receptors: a FRET-based investigation of conformational changes.

Authors:  Gomathi Ramanoudjame; Mei Du; Kimberly A Mankiewicz; Vasanthi Jayaraman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-22       Impact factor: 11.205

4.  Automatic atom type and bond type perception in molecular mechanical calculations.

Authors:  Junmei Wang; Wei Wang; Peter A Kollman; David A Case
Journal:  J Mol Graph Model       Date:  2006-02-03       Impact factor: 2.518

5.  Rigid body essential X-ray crystallography: distinguishing the bend and twist of glutamate receptor ligand binding domains.

Authors:  Esben J Bjerrum; Philip C Biggin
Journal:  Proteins       Date:  2008-07

6.  Crystal structures of the GluR5 and GluR6 ligand binding cores: molecular mechanisms underlying kainate receptor selectivity.

Authors:  Mark L Mayer
Journal:  Neuron       Date:  2005-02-17       Impact factor: 17.173

7.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Mol Biol       Date:  1995-01-06       Impact factor: 5.469

8.  Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.

Authors:  Brianne Weiss; Andrew Alt; Ann Marie Ogden; Mary Gates; Donna K Dieckman; Amy Clemens-Smith; Ken H Ho; Keith Jarvie; Geihan Rizkalla; Rebecca A Wright; David O Calligaro; Darryle Schoepp; Edward L Mattiuz; Robert E Stratford; Bryan Johnson; Craig Salhoff; Mary Katofiasc; Lee A Phebus; Kathryn Schenck; Marlene Cohen; Sandra A Filla; Paul L Ornstein; Kirk W Johnson; David Bleakman
Journal:  J Pharmacol Exp Ther       Date:  2006-05-11       Impact factor: 4.030

9.  AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans.

Authors:  C N Sang; M P Hostetter; R H Gracely; A S Chappell; D D Schoepp; G Lee; S Whitcup; R Caruso; M B Max
Journal:  Anesthesiology       Date:  1998-11       Impact factor: 7.892

10.  In vitro characterization of 5-carboxyl-2,4-di-benzamidobenzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors.

Authors:  Jeppe K Christensen; Thomas Varming; Philip K Ahring; Tino D Jørgensen; Elsebet Ø Nielsen
Journal:  J Pharmacol Exp Ther       Date:  2004-02-25       Impact factor: 4.030

View more
  11 in total

Review 1.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

2.  Pharmacological activity of C10-substituted analogs of the high-affinity kainate receptor agonist dysiherbaine.

Authors:  L Leanne Lash-Van Wyhe; Pekka A Postila; Koichi Tsubone; Makoto Sasaki; Olli T Pentikäinen; Ryuichi Sakai; Geoffrey T Swanson
Journal:  Neuropharmacology       Date:  2009-12-04       Impact factor: 5.250

3.  The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening.

Authors:  Gordon Wells; Hongjie Yuan; Miranda J McDaniel; Hirofumi Kusumoto; James P Snyder; Dennis C Liotta; Stephen F Traynelis
Journal:  Proteins       Date:  2018-10-05

4.  Binding site and ligand flexibility revealed by high resolution crystal structures of GluK1 competitive antagonists.

Authors:  Gregory M Alushin; David Jane; Mark L Mayer
Journal:  Neuropharmacology       Date:  2010-06-15       Impact factor: 5.250

5.  Selective effect of cell membrane on synaptic neurotransmission.

Authors:  Pekka A Postila; Ilpo Vattulainen; Tomasz Róg
Journal:  Sci Rep       Date:  2016-01-19       Impact factor: 4.379

6.  Discovery of Retinoic Acid-Related Orphan Receptor γt Inverse Agonists via Docking and Negative Image-Based Screening.

Authors:  Sanna Rauhamäki; Pekka A Postila; Sakari Lätti; Sanna Niinivehmas; Elina Multamäki; Klaus R Liedl; Olli T Pentikäinen
Journal:  ACS Omega       Date:  2018-06-11

7.  Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives.

Authors:  Sanna Niinivehmas; Pekka A Postila; Sanna Rauhamäki; Elangovan Manivannan; Sami Kortet; Mira Ahinko; Pasi Huuskonen; Niina Nyberg; Pasi Koskimies; Sakari Lätti; Elina Multamäki; Risto O Juvonen; Hannu Raunio; Markku Pasanen; Juhani Huuskonen; Olli T Pentikäinen
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

8.  Structural mechanism of N-methyl-D-aspartate receptor type 1 partial agonism.

Authors:  Mikko Ylilauri; Olli T Pentikäinen
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

9.  Atomistic determinants of co-enzyme Q reduction at the Qi-site of the cytochrome bc1 complex.

Authors:  Pekka A Postila; Karol Kaszuba; Patryk Kuleta; Ilpo Vattulainen; Marcin Sarewicz; Artur Osyczka; Tomasz Róg
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

10.  Neurotransmitter Funneling Optimizes Glutamate Receptor Kinetics.

Authors:  Alvin Yu; Héctor Salazar; Andrew J R Plested; Albert Y Lau
Journal:  Neuron       Date:  2017-12-14       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.